Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Y-Mabs Therapeutics Inc’s stock clocked out at $6.20, down -0.64% from its previous closing price of $6.24. In other words, the price has decreased by -$0.64 from its previous closing price. On the day, 0.69 million shares were traded.
Ratios:
To gain a deeper understanding of YMAB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.54 and its Current Ratio is at 3.92. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on November 18, 2024, initiated with a Outperform rating and assigned the stock a target price of $23.
On August 16, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $20.
On June 28, 2024, Truist started tracking the stock assigning a Buy rating and target price of $21.Truist initiated its Buy rating on June 28, 2024, with a $21 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 13 ’24 when Gad Thomas sold 65,000 shares for $13.47 per share. The transaction valued at 875,550 led to the insider holds 97,681 shares of the business.
Gad Thomas sold 30,000 shares of YMAB for $389,100 on Sep 16 ’24. The CHIEF BUSINESS OFFICER now owns 67,681 shares after completing the transaction at $12.97 per share. On Sep 13 ’24, another insider, Thomas Gad, who serves as the Officer of the company, bought 100,000 shares for $13.74 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.28 while its Price-to-Book (P/B) ratio in mrq is 3.00.
Stock Price History:
Over the past 52 weeks, YMAB has reached a high of $20.90, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is -16.99%, while the 200-Day Moving Average is calculated to be -46.41%.
Shares Statistics:
A total of 44.77M shares are outstanding, with a floating share count of 34.10M. Insiders hold about 23.87% of the company’s shares, while institutions hold 60.27% stake in the company.
Earnings Estimates
The dynamic stock of Y-Mabs Therapeutics Inc (YMAB) is currently attracting attention from 10.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.04 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.24 and -$0.75 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.55, with 10.0 analysts recommending between -$0.23 and -$0.94.
Revenue Estimates
In the current quarter, 8 analysts expect revenue to total $26.7M. It ranges from a high estimate of $28M to a low estimate of $25M. As of the current estimate, Y-Mabs Therapeutics Inc’s year-ago sales were $23.36MFor the next quarter, 8 analysts are estimating revenue of $24.37M. There is a high estimate of $28.8M for the next quarter, whereas the lowest estimate is $22M.
A total of 10 analysts have provided revenue estimates for YMAB’s current fiscal year. The highest revenue estimate was $90.5M, while the lowest revenue estimate was $86M, resulting in an average revenue estimate of $88.4M. In the same quarter a year ago, actual revenue was $84.82MBased on 11 analysts’ estimates, the company’s revenue will be $105.76M in the next fiscal year. The high estimate is $118.43M and the low estimate is $97M.
